Smith K J, Skelton H G, Yeager J, Ledsky R, Ng T H, Wagner K F
United States Army Medical Research Institute for Chemical Defense, Aberdeen, Maryland, USA.
Clin Exp Dermatol. 1997 May;22(3):118-23.
Drug reactions are common in HIV-1 disease, with the incidence having been reported to increase with increasing stage and with CD4+ T-cell counts below 200/microliters. However, there have been numerous reports of patients in which rechallenge, dosing changes or continued therapy have resulted in no recurrence or else clearing of the eruption. We followed 974 HIV-1-positive patients for 46 months as a part of a military study of HIV-1 disease. Within this group there were a total of 283 drug eruptions, with cutaneous manifestations in 201 patients in which clinical characteristics were noted and 86 patients in which cutaneous biopsies were performed. Serological evidence of reactivation or acute Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infections were also noted, as well as peripheral eosinophilia. The incidence of drug eruptions significantly increased with increasing Walter Reed stage and decreasing CD4 counts and CD4/CD8 ratio, as well as with increasing age and in patients with increased numbers of other dermatological diagnoses. In addition, white patients had significantly more drug eruptions than did black. Serological or culture evidence of acute or reactivated EBV or CMV was significantly increased in patients with drug eruptions. The majority of the eruptions were maculopapular or morbilliform with a predominantly perivascular mononuclear cell infiltrate. HIV-1 positive patients have an increased incidence of drug reactions, the incidence having been reported to increase in patients with less than 200 CD4+ T cells/microliter. However, at very low T4 counts, especially those less than 25/microliter, and at a CD4/CD8 ratio of less than 0.10, the probability of reactions to trimethoprim-sulphamethoxazole (TMP-SMZ) is decreased in late-stage HIV-1 patients. Maculopapular or morbilliform eruptions are the most common clinical presentations, often accompanied by one or more of the following: fever, arthralgias, eosinophilia, and serum transaminase elevation. Histologically the majority of these eruptions show a perivascular mononuclear cell infiltrate, sometimes with focal interface changes and apoptotic, necrotic cells within the epidermis. Acute hypersensitivity reactions and toxic epidermal necrolysis (TEN) or Stevens-Johnson's syndrome (SJS) with diffuse epidermal apoptosis and necrosis have also been less commonly described. In a study of cutaneous manifestations in an HIV-1 positive military population, drug reactions were evaluated in terms of clinical features, histopathology, demographic features and laboratory findings.
药物反应在HIV-1疾病中很常见,据报道其发生率随着疾病分期的增加以及CD4+T细胞计数低于200/微升而上升。然而,有许多关于患者的报告显示,再次用药、调整剂量或继续治疗并未导致皮疹复发或消退。作为一项HIV-1疾病军事研究的一部分,我们对974名HIV-1阳性患者进行了46个月的随访。在这个队列中,共有283例药物疹,其中201例有皮肤表现并记录了临床特征,86例进行了皮肤活检。还注意到了病毒再激活或急性爱泼斯坦-巴尔病毒(EBV)或巨细胞病毒(CMV)感染的血清学证据以及外周嗜酸性粒细胞增多。药物疹的发生率随着沃尔特·里德分期的增加、CD4计数和CD4/CD8比值的降低、年龄的增长以及其他皮肤病诊断数量的增加而显著上升。此外,白人患者的药物疹明显多于黑人。药物疹患者中急性或再激活的EBV或CMV的血清学或培养证据显著增加。大多数皮疹为斑丘疹或麻疹样,主要有血管周围单核细胞浸润。HIV-1阳性患者的药物反应发生率增加,据报道CD4+T细胞低于200/微升的患者发生率更高。然而,在T4细胞计数非常低时,尤其是低于25/微升,且CD4/CD8比值低于0.10时,晚期HIV-1患者对复方新诺明(TMP-SMZ)发生反应的可能性降低。斑丘疹或麻疹样皮疹是最常见的临床表现,常伴有以下一种或多种症状:发热、关节痛、嗜酸性粒细胞增多和血清转氨酶升高。组织学上,这些皮疹大多数显示血管周围单核细胞浸润,有时伴有局灶性界面改变以及表皮内的凋亡、坏死细胞。急性超敏反应以及伴有弥漫性表皮凋亡和坏死的中毒性表皮坏死松解症(TEN)或史蒂文斯-约翰逊综合征(SJS)也较少见。在一项对HIV-1阳性军事人群皮肤表现的研究中,从临床特征、组织病理学、人口统计学特征和实验室检查结果等方面对药物反应进行了评估。